A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

NCT04756323 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: medium dosage inactivated SARS-CoV-2 vaccine
BIOLOGICAL: high dosage inactivated SARS-CoV-2 vaccine
BIOLOGICAL: Placebo

Sponsor

Beijing Minhai Biotechnology Co., Ltd

Collaborators

[object Object]
[object Object]